Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Tislelizumab, an anti‐programmed death protein‐1 (PD‐1) monoclonal antibody, was engineered to minimize binding to the FcγR on macrophages to abrogate antibody‐dependent phagocytosis, a mechanism of T‐cell clearance and potential resistance to anti‐PD‐1 therapy. This single‐arm phase 2 trial (NCT040...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Ye, Dingwei, Liu, Jiyan, Zhou, Aiping, Zou, Qing, Li, Hanzhong, Fu, Cheng, Hu, Hailong, Huang, Jian, Zhu, Shaoxing, Jin, Jie, Ma, Lulin, Guo, Jianming, Xiao, Jun, Park, Se Hoon, Zhang, Dahong, Qiu, Xiusong, Bao, Yuanyuan, Zhang, Lilin, Shen, Wei, Bi, Feng
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Clinical Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7780053/
https://ncbi.nlm.nih.gov/pubmed/33047430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14681
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi